The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy.
Alp E., Gonen ZB., Gundogan K., Esmaoglu A., Kaynar L., Cetin A.
Clinical Trial with a reported sample of 20, published in Emerg Med Int (2022) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Emerg Med Int (2022)
- Country
- United States
- Reported sample size
- 20
- Source database
- PubMed
- PMID
- 35784641
- DOI
- 10.1155/2022/9222379
- NCT
- NCT05283317
Abstract (original English)
Sepsis and septic shock are the major causes of death in intensive care units. This study aimed to evaluate the clinical safety and efficacy of mesenchymal stem cells (MSCs) in sepsis and septic shock patients. Ten patients were enrolled in the study. Adipose-derived MSC infusions were given (1 × 10 6 /kg, on the 1 st , 3 rd , 5 th , 7 th , and 9 th days of therapy) together with standard therapy. Before the MSC applications, blood samples were collected for cytokine assessment (TNF- α , IFN- γ , IL-2, IL-4, IL-6, IL-10). The clinical and laboratory improvements were recorded and compared with control groups selected retrospectively. The clinical trial was registered on 16.03.2022 with the registration number NCT05283317. In the study group, the ages of patients ranged from 22 to 68 years, and APACHE II scores ranged from 14 to 42. In the control group, ages ranged from 22 to 80 years and their APACHE II scores were between 14-35. The survival rate in the study group was 100% on the 14 th day whereas it was 70% on the 28 th day. A significant decrease in the SOFA score (adjusted), clinical, and laboratory improvements were observed during the MSC administration. However, no significant cytokine level changes were observed. In the control group, the survival rate of 20 patients was 70% on the 14 th day, whereas 60% was on the 28 th day. While deaths were observed in the control
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.